Search clinical trials for: Optimal Human Challenge Dose

Total 45604 results

National Institute of Allergy and Infectious Diseases...

Completed

Phase I Norovirus Challenge Model

Gastroenteritis Norovirus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

Gastroenteritis Norovirus

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

Gastroenteritis Norovirus

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Hvivo
Pfizer

Recruiting

Dose, Safety, and Pathogenicity of a New Influenza B Strain

Influenza B

United Kingdom
Ifakara Health Institute
University of Oxford

Not yet recruiting

In-vivo Transmission Model in Semi-immune Adults

Controlled Human Malaria Infection | Malaria Transmission | Induced Blood Stage Malaria Infection | Malaria Challenge

Tanzania
Humanitas Clinical and Research Center
Società Italiana Anestesia, Analgesia, Rianimazione e Terapia Intensiva -...

Recruiting

HIgh Versus STAndard Blood Pressure Target in Hypertensive High-risk Patients Undergoing Major Abdominal Surgery (HISTAP)

Blood Pressure | Complication,Postoperative | Intraoperative Hypotension

Italy
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

Tuberculosis | Rifampicin Resistant Tuberculosis

Brazil, India, South Africa, Tanzania, Thailand
Stellah Mpagama
Radboud University Medical Center; University of St Andrews

Recruiting

A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis (OptiRiMoxTB)

Tuberculosis | Human Immunodeficiency Virus

Tanzania
Green Cross Wellbeing

Recruiting

Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Chronic Liver Disease

Korea, Republic of
Phost'In Therapeutics

Recruiting

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (PhAST)

Glioblastoma Multiforme | Metastatic Cancer | Advanced Solid Tumor | Malignant Tumor

Italy, France
Children's Hospital Medical Center, Cincinnati
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

Fragile X Syndrome

United States
NewAmsterdam Pharma
Monash University

Recruiting

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

Atherosclerotic Cardiovascular Disease

United States, Israel, Italy, Spain, Canada, Czechia, Poland, China, Denmark, Netherlands, Finland, Japan, Australia, Hungary, Germany, Croatia, United Kingdom, Bulgaria, South Africa, Georgia, Jordan, Slovakia, Latvia
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
University of Maryland, Baltimore
Medical Technology Enterprise Consortium (MTEC)

Completed

Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

Dengue

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Evandro Chagas National Institute of Infectious... and other collaborators

Active, not recruiting

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial (OPTIMO)

HIV Infection

Peru, Brazil, Haiti
Janssen Research & Development, LLC

Suspended

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

Healthy

United States, United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants

Healthy

Australia
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Hvivo
Pfizer

Completed

Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain

Influenza A H1N1

United Kingdom
Merck Sharp & Dohme LLC

Completed

Hepatitis B Challenge Dose in Adults (V232-059-10)

Hepatitis B
Cerevel Therapeutics, LLC

Completed

A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects

Panic Disorder

Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

H1N1v Virus Challenge Study in Healthy Subjects

Influenza

United States
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
Radboud University Medical Center
The PATH Malaria Vaccine Initiative (MVI); QIMR Berghofer Medical Research...

Completed

Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 (CHMI-trans2)

Transmission | Malaria,Falciparum | Controlled Human Malaria Infection | Gametocytes

Netherlands
Janssen BioPharma, Inc.

Completed

A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants

Healthy

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy

Hepatitis B

Germany
WCCT Global
National Institutes of Health (NIH); Stanford University

Completed

Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus

Influenza
National Institute of Allergy and Infectious Diseases...

Completed

Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers

Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2

United States
Sanaria Inc.
University of Maryland; Walter Reed Army Institute of Research (WRAIR); Naval... and other collaborators

Completed

PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine

Hepatitis B

Australia, Belgium
GlaxoSmithKline

Completed

Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children

Hepatitis B

Slovakia
GlaxoSmithKline

Completed

Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™

Hepatitis B | Hepatitis A

Belgium, Czechia
GlaxoSmithKline

Completed

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Hepatitis B | Hepatitis A

Belgium, Czechia
GlaxoSmithKline

Completed

Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.

Hepatitis B Vaccine

Germany
GlaxoSmithKline

Completed

Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children

Hepatitis B

Germany
Radboud University Medical Center
The PATH Malaria Vaccine Initiative (MVI); QIMR Berghofer Medical Research...

Completed

Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1 (CHMI-trans1)

Malaria

Netherlands
Alios Biopharma Inc.

Completed

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Influenza

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA

Virus Diseases | Hepatitis B

Italy
GlaxoSmithKline

Completed

Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.

Hepatitis B

Thailand
Sanaria Inc.
Swiss Tropical & Public Health Institute; Ifakara Health Institute; Tanzania...

Completed

Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

Malaria | Plasmodium Falciparum Malaria

Tanzania
Aristotle University Of Thessaloniki
Eugonia IVF Unit, Athens, Greece

Unknown

Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients (ATD)

Subfertility

Greece
Halozyme Therapeutics

Completed

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
UMN Pharma Inc.

Completed

Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

Virus Diseases | Influenza

Japan
Oxagen Ltd

Completed

OC000459 Dose Finding Study in Hay Fever Sufferers.

Allergic Rhinitis

Austria
Bronx VA Medical Center

Not yet recruiting

Dose Optimization of MDMA-Assisted Therapy for PTSD (DosOp)

Posttraumatic Stress Disorder
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
Serum Institute of India Pvt. Ltd.

Recruiting

Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Hepatitis B Immunization | Diptheria Immunization | Tetanus Immunization | Pertussis Immunization | Haemophilus Influenzae Type B Immunization | Polio Immunization

Bangladesh, India
Centre for Human Drug Research, Netherlands

Recruiting

Deep Phenotyping of Cutaneous Lupus Erythematosus

Cutaneous Lupus Erythematosus

Netherlands

3

Subscribe